Get the Stockscreener App
32.15
1.77%
0.56
Eton Pharmaceuticals Inc stock is traded at $32.15, with a volume of 263.22K.
It is up +1.77% in the last 24 hours and up +6.25% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$31.59
Open:
$31.79
24h Volume:
263.22K
Relative Volume:
0.63
Market Cap:
$880.66M
Revenue:
$86.93M
Net Income/Loss:
$-1.48M
P/E Ratio:
-453.46
EPS:
-0.0709
Net Cash Flow:
$431.00K
1W Performance:
+7.35%
1M Performance:
+6.25%
6M Performance:
+101.57%
1Y Performance:
+124.83%
1-Day Range:
$30.89
$32.18
1-Week Range:
$29.06
$32.78
52-Week Range:
$13.09
$35.66
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
32.15 | 880.66M | 86.93M | -1.48M | 431.00K | -0.0709 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharmaceuticals (ETON) surges 19.8%: Is this an indication of further gains? - MSN
Eton Pharmaceuticals (ETON) Surges 4.75% as Momentum Builds Toward ResistanceWatchlist Stock Ideas - newsline.com
Trading the Move, Not the Narrative: (ETON) Edition - Stock Traders Daily
Eton Pharmaceuticals (NASDAQ: ETON) 2026 vote supports board and auditor - Stock Titan
Eton Pharmaceuticals (ETON) Gains 2.8% as Bullish Momentum Builds Toward ResistanceHigh Beta Stocks - newsline.com
Eton Pharmaceuticals Rallies as Stock Approaches Key Resistance (ETON)Total Put Call - newsline.com
Eton Pharmaceuticals (ETON) Holds Steady Near Resistance With Modest GainDividend ETF - newsline.com
ETON Q1 2026 Earnings: EPS Misses Estimates Despite Narrow ProfitCore Business Growth - newsline.com
Possible Bearish Signals With Eton Pharmaceuticals Insiders Disposing Stock - simplywall.st
ETON: Aggressively scaling rare disease portfolio with strong sales, margin growth, and patient focus - TradingView
[144] Eton Pharmaceuticals, Inc. SEC Filing - Stock Titan
Eton Pharmaceuticals (ETON) CFO reports 37,000 employee stock options - Stock Titan
Eton Pharmaceuticals CEO Sean Brynjelsen sells $3.83 million in stock - Investing.com India
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Scor - GuruFocus
Eton Pharmaceuticals CEO Sean Brynjelsen sells $3.83 million in stock By Investing.com - Investing.com South Africa
(ETON) Volatility Zones as Tactical Triggers - Stock Traders Daily
Eton Pharmaceuticals (ETON) CEO reports open-market sale of 120,000 shares - Stock Titan
120,000 ETON shares proposed for sale by affiliate (ETON) - Stock Titan
Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG - MarketBeat
Eton Pharmaceuticals Insider Sold Shares Worth $3,229,923, According to a Recent SEC Filing - Moomoo
Eton Pharmaceuticals CBO David Krempa sells $3.2m in stock By Investing.com - Investing.com Canada
Eton (ETON) CBO sells 100,000 shares after exercising 87,794 options - Stock Titan
Eton Pharmaceuticals (ETON) soars 6.7%: Is further upside left in the stock? - MSN
ETON SEC FilingsEton Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy - Insider Monkey
Eton Pharmaceuticals Inc (ETON) Shares Fall 6.9% -- GF Value Says Still Overvalued - GuruFocus
ETON (Nasdaq) Rule 144 shows RSUs and Options grants dated 2024–2026 - Stock Titan
5 Oversold Growth Stocks to Invest In Now - Insider Monkey
H.C. Wainwright reiterates Eton Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results By Investing.com - Investing.com Nigeria
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results - Investing.com
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug By Investing.com - Investing.com India
Eton Pharmaceuticals, Inc.Common Stock (NQ: ETON - The Chronicle-Journal
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug - Investing.com
Eton Pharmaceuticals Obtains US Commercialization Rights to Impavido - Moomoo
Eton (NASDAQ: ETON) licenses U.S. IMPAVIDO rights in rare disease push - Stock Titan
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) - The Manila Times
Eton Pharmaceuticals Announces U.S. Commercialization Rights for IMPAVIDO®, First FDA-Approved Oral Therapy for Leishmaniasis - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Price-Driven Insight from (ETON) for Rule-Based Strategy - Stock Traders Daily
H.C. Wainwright raises Eton Pharmaceuticals stock price target to $57 By Investing.com - Investing.com Canada
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2026 Earnings Call Transcript - Insider Monkey
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):